Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetylcarnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.96 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.50 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcarnitine SCHEMBL1330152 | 1.00 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL951660 | 1.00 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL1331768 | 1.00 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL9300885 | 1.00 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL387375 | 1.00 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL69781 | 0.98 | MEN1 (1.00) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL118455 | 0.98 | MEN1 (1.00) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL677128 | 0.98 | MEN1 (1.00) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL28017793 | 0.98 | MEN1 (1.00) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL3004014 | 0.96 | MEN1 (0.96) | MEN1KMT2ACYP1A2HRH1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100350915-C | Medicine for treating metabolism syndrome | LIAONING YILIAN NOVEL MEDICINE (CN) | 2007-11-28 | — | — | CN | claimed |
| CN-1238055-C | Medicine for curing metabolic syndrome | LIAONING YILIAN NEW MEDICINE I (CN) | 2006-01-25 | — | — | CN | claimed |
| CN-1443575-A | Medicine for curing metabolic syndrome | LIAONING YILIAN NEW MEDICINE I (CN) | 2003-09-24 | — | — | CN | claimed |
| CN-1433766-A | Medicine for treating metabolism syndrome | LIAONING YILIAN NOVEL MEDICINE (CN) | 2003-08-06 | — | — | CN | claimed |
| US-20030040507-A1 | Pharmaceutical composition comprising ifosfamide and carnitine | NICKEL BERND (DE) | 2003-02-27 | — | — | US | claimed |
| JP-63267716-A | — | — | None | — | — | JP | disclosed |
| CN-119097619-A | Application of acetyl carnitine in preparing medicine for preventing and/or treating inflammatory bowel disease | 中国人民解放军海军军医大学 | 2024-12-10 | — | — | CN | disclosed |
| CN-117084953-A | Hair care or hair cleaning composition or skin care or skin cleaning composition | 魏德曼控股股份公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-116919865-A | Dry mixture | 魏德曼控股股份公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-110505868-B | Personal care compositions | 魏德曼控股股份公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-110505868-A | Personal care compositions | WEIDMANN HOLDING AG | 2019-11-26 | — | — | CN | disclosed |
| CN-109796356-A | The new process of spray drying production carnitine | 刘畅 | 2019-05-24 | — | — | CN | disclosed |
| WO-2004026114-A2 | QUANTIFICATION OF CARNITINE LEVELS IN DIALYSIS PATIENTS | SIGMA-TAU PHARMACEUTICALS, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| CN-1443575-A | Medicine for curing metabolic syndrome | LIAONING YILIAN NEW MEDICINE I (CN) | 2003-09-24 | — | — | CN | disclosed |
| CN-1433766-A | Medicine for treating metabolism syndrome | LIAONING YILIAN NOVEL MEDICINE (CN) | 2003-08-06 | — | — | CN | disclosed |
| US-20030129762-A1 | Quantification of carnitine levels in dialysis patients | SIGMA-TAU PHARMACEUTICALS INC. | 2003-07-10 | — | — | US | disclosed |
| CN-1408704-A | Process for preparing acetyl levocarnitine hydrochlorate | DONGBEI PHARMACEUTICAL GENERAL (CN) | 2003-04-09 | — | — | CN | disclosed |
| JP-S63267716-A | REMEDY FOR UREA CYCLE DYSBOLISM | EARTH CHEM CORP LTD | 1988-11-04 | — | — | JP | disclosed |
| US-4721728-A | ANTILIPEMIC AGENTS, METABOLISM | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.P.A. (IT) | 1988-01-26 | — | — | US | disclosed |
| EP-0220538-A1 | New pantothenyl derivatives | S P A SOCIETA' PRODOTTI ANTIBIOTICI S.p.a. (IT) | 1987-05-06 | — | — | EP | disclosed |